Physician profile
Pinchas Rosenberg
NPI 1972528222
$4,606.50
in general payments reported to CMS, 2019-2025
16 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $294 · 2021: $439 · 2022: $595 · 2023: $665 · 2024: $1,233 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,961.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,399.31 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $420.95 | 2022-2025 | Vabysmo |
| Astellas Pharma US INC | $356.59 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $312.51 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $277.98 | 2022-2025 | Syfovre |
| Abbvie INC. | $192.00 | 2022-2025 | Ozurdex |
| Sandoz INC. | $149.87 | 2024 | Cimerli |
| Harrow Eye, LLC | $147.41 | 2025 | Iheezo, Triesence |
| Alimera Sciences, INC. | $125.68 | 2019-2024 | Iluvien, Yutiq |
| Ani Pharmaceuticals, INC. | $84.63 | 2025 | Iluvien, Yutiq |
| Genentech, INC. | $49.29 | 2021-2025 | Vabysmo |
| Coherus Oncology, INC. | $24.24 | 2024 | |
| Eyepoint US, INC. | $19.62 | 2022 | |
| Quidel Corporation | $16.79 | 2019 | |
| Horizon Therapeutics Plc | $15.12 | 2023 | Tepezza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $14.51 | 2024 | Ryzumvi, Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pinchas Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.